



Rexahn Pharmaceuticals, Inc.
Investor Relations Department
15245 Shady Grove Road, Suite
455
Rockville, MD 20850
United States

Visit IR website [↗](#)
Sign-up for email alerts [↗](#)

AMEX: RNN

| | |
|---------------|------------------------|
| Last Trade: | 1.83 |
| Trade Time: | 8:00 PM ET 08/21/17 |
| Change: | -0.03 ↓ (1.613%) |
| Day Range | 1.80 - 1.86 |
| 52-Week Range | 1.27 - 7.10 |
| Volume | 90,571 |

Stock information is provided by eSignal,
stock charts provided by EDGAR Online.
Stock data is delayed approximately 20
minutes.

Company Profile

Rexahn Pharmaceuticals is a clinical stage biopharmaceutical company dedicated to developing best-in-class therapeutics for the treatment of cancer. Rexahn currently has three clinical stage oncology candidates, Archexin®, RX-3117, and Supinoxin™ (RX-5902) and a robust pipeline of preclinical compounds to treat multiple types of cancer.

... [\(more\)](#)

Stock Performance



Press Releases [\[View all \]](#)

08/14/17

[Rexahn Pharmaceuticals Issues Mid-Year Shareholder Letter to Review Recent Progress and Clinical Plans](#)

08/07/17

[Rexahn Pharmaceuticals Reports Second Quarter 2017 Financial and Operational Results](#)

07/10/17

[Rexahn Pharmaceuticals Receives Notice of Allowance for a New U.S. Patent Covering the Use of RX-3117](#)

06/07/17

[Rexahn Announces \\$10 Million Registered Direct Offering](#)

06/04/17

[Rexahn Pharmaceuticals Presents Preliminary Efficacy Data from the Ongoing Phase IIa Clinical Trial of RX-3117 in Metastatic Bladder Cancer at the American Society of Clinical Oncology \(ASCO\) 2017 Annual Meeting](#)

Financials [\[View all \]](#)

[Fourth Quarter Financial Results](#)

02/24/17

[Annual Report \(10-K\)](#)

02/24/17

[Proxy Statement \(DEF 14A\)](#)

08/04/17

[Quarterly Report \(10-Q\)](#)

05/03/17

[Quarterly Report \(10-Q\)](#)

11/04/16

[Quarterly Report \(10-Q\)](#)